Clinical Trial Detail

NCT ID NCT02123758
Title A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer
Recruitment Active, not recruiting
Gender male
Phase Phase I
Variant Requirements No
Sponsors Aragon Pharmaceuticals, Inc.
Indications

prostate adenocarcinoma

Therapies

Abiraterone + Apalutamide + Prednisone

Age Groups: adult

No variant requirements are available.